GF Fund Management’s Mineralys Therapeutics MLYS Stock Holding History

GF Fund Management’s Portfolio MLYS Stock Details MLYS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$45.2K	Sell	1,676 -101	-6%	-$2.77K	﹤0.01%	398
2026 Q1	$48.1K	Buy	1,777 +222	+14%	+$6.51K	﹤0.01%	404
2025 Q4	$56.4K	Buy	1,555 +129	+9%	+$5.17K	﹤0.01%	396
2025 Q3	$54.1K	Buy	1,426 +152	+12%	+$3.29K	﹤0.01%	387
2025 Q2	$17.2K	Hold	1,274	–	–	﹤0.01%	517
2025 Q1	$20.2K	Buy	1,274 +229	+22%	+$2.63K	﹤0.01%	503
2024 Q4	$12.9K	Buy	+1,045	New	+$13.7K	﹤0.01%	517

Other funds holding MLYS

Catalys Pacific Tokyo, Japan $229M AUM 100.3% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

LCM

Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

GF Fund Management's MLYS Position: Q2 2026 in Review

GF Fund Management reduced its Mineralys Therapeutics (MLYS) stake by 5.7% in Q2 2026, selling an estimated $2.77K and leaving 1,676 shares worth $45.2K. The position accounts for ﹤0.01% of the portfolio, ranked #398.

GF Fund Management first reported a position in MLYS in Q4 2024 and has held it in 7 quarters since. The position peaked at $56.4K in Q4 2025. 224 funds tracked by Wall St. Rank hold MLYS as of Q2 2026.

GF Fund Management held 1,676 shares of Mineralys Therapeutics worth $45.2K as of Q2 2026.
GF Fund Management sold 101 Mineralys Therapeutics shares in Q2 2026, an estimated $2.77K.
Mineralys Therapeutics made up ﹤0.01% of GF Fund Management's portfolio in Q2 2026, its #398 holding.
GF Fund Management first reported a position in Mineralys Therapeutics in Q4 2024 and has held it in 7 quarters since.
GF Fund Management's Mineralys Therapeutics position peaked at $56.4K in Q4 2025.
224 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q2 2026.

Based on GF Fund Management's 13F filing for Q2 2026, filed 7 Aug 2026.